791 related articles for article (PubMed ID: 21149668)
1. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Gangat N; Caramazza D; Vaidya R; George G; Begna K; Schwager S; Van Dyke D; Hanson C; Wu W; Pardanani A; Cervantes F; Passamonti F; Tefferi A
J Clin Oncol; 2011 Feb; 29(4):392-7. PubMed ID: 21149668
[TBL] [Abstract][Full Text] [Related]
2. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
3. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
4. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
5. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
6. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
Tefferi A; Huang J; Schwager S; Li CY; Wu W; Pardanani A; Mesa RA
Cancer; 2007 May; 109(10):2083-8. PubMed ID: 17407134
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
8. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis.
Wang J; Xu J; Gale RP; Xu Z; Li B; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Qu S; Zhang P; Xiao Z
Leuk Res; 2014 Oct; 38(10):1207-11. PubMed ID: 25182689
[TBL] [Abstract][Full Text] [Related]
10. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
12. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
[TBL] [Abstract][Full Text] [Related]
13. [A study of prognostic value of cytogenetics in patients with primary myelofibrosis].
Li B; Xu J; Xu Z; Li C; Qin T; Fang L; Zhang H; Hu N; Pan L; Qu S; Wang J; Zhang Y; Zhang P; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):990-4. PubMed ID: 25417875
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
15. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A
Blood; 2010 Mar; 115(9):1703-8. PubMed ID: 20008785
[TBL] [Abstract][Full Text] [Related]
16. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method.
Kreft A; Weiss M; Wiese B; Choritz H; Buhr T; Büsche G; Georgii A
Ann Hematol; 2003 Oct; 82(10):605-11. PubMed ID: 14564478
[TBL] [Abstract][Full Text] [Related]
17. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
Pardanani A; Lasho TL; Finke CM; Rajkumar SV; Singh PP; Ketterling RP; Hanson CA; Katzmann JA; Tefferi A
J Clin Oncol; 2012 Apr; 30(10):1087-94. PubMed ID: 22331938
[TBL] [Abstract][Full Text] [Related]
18. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
Tefferi A; Mesa RA; Pardanani A; Hussein K; Schwager S; Hanson CA; Steensma DP
Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
[TBL] [Abstract][Full Text] [Related]
19. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
Tadmor T; Shvidel L; Aviv A; Ruchlemer R; Bairey O; Yuklea M; Herishanu Y; Braester A; Rahimi-Levene N; Vernea F; Ben-Ezra J; Bejar J; Polliack A;
Cancer; 2013 May; 119(10):1853-9. PubMed ID: 23423815
[TBL] [Abstract][Full Text] [Related]
20. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
Tefferi A; Dingli D; Li CY; Dewald GW
Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]